10 stories mentioning RLAYUpdated 14d ago
Every FINWIRES story that references RLAY, newest first.
Relay Therapeutics (RLAY) has an average rating of buy and mean price target of $25.38, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Thomas Catinazzo, Chief Financial Officer, on July 06, 2026, sold 17,717 shares in Relay Therapeutics (RLAY) for $331,131. Following the Form 4 filing with the SEC, Catinazzo has control over a total of 159,744 common shares of the company, with 159,744 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1812364/000119312526298679/xslF345X05/ownership.xml
Sanjiv Patel, Director, President, and CEO, on July 07, 2026, sold 48,199 shares in Relay Therapeutics (RLAY) for $943,736. Following the Form 4 filing with the SEC, Patel has control over a total of 1,502,801 common shares of the company, with 615,898 shares held directly and 886,903 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1812364/000119312526298681/xslF345X05/ownership.xml
Donald A Bergstrom, President, R&D, on June 22, 2026, sold 93,456 shares in Relay Therapeutics (RLAY) for $1,583,145. Following the Form 4 filing with the SEC, Bergstrom has control over a total of 418,557 common shares of the company, with 418,557 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1812364/000119312526281059/xslF345X05/ownership.xml
Healthcare stocks were declining premarket Thursday, with the iShares Biotechnology ETF (IBB) 1% lower and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1%.Immix Biopharma (IMMX) shares were up more than 6% after the company said it achieved a 95% complete response rate in a phase 1b/2 trial evaluating NXC-201 for the treatment for relapsed/refractory AL Amyloidosis.Nanobiotix (NBTX) launched a global follow-on offering of 75 million euros ($87.2 million), the clinical-stage biotechnology company said. Nanobiotix stock was down more than 5% pre-bell.Relay Therapeutics (RLAY) shares were up more than 10% after the company said it priced a public offering of 22.9 million common shares at $12 each.
Relay Therapeutics (RLAY) launched an underwritten public offering of $175 million of common stock.Underwriters are set to receive a 30-day option to buy up to an additional 15% of the offering, the company said Tuesday in a statement.Relay shares fell 4.1% in after-hours trading.
Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) gaining 1.2%.The iShares Biotechnology ETF (IBB) increased 0.5%.In sector news, Nourish, a nutrition counseling startup focused on supporting patients using GLP-1 weight-loss drugs, raised $100 million in a Series C funding round led by Menlo Ventures, the company said Tuesday. The round included participation from Thrive Capital, Index Ventures, JPMorgan Chase's (JPM) growth equity arm, Maverick Ventures, Y Combinator and others, the company said.In corporate news, Boston Scientific (BSX) shares gained 1.4% after the company said Tuesday that a trial evaluating its investigational catheter for treating severe coronary artery disease met primary safety and effectiveness endpoints.Relay Therapeutics (RLAY) shares climbed 5.2% after it said early phase 2 data showed its experimental drug zovegalisib reduced lesion volume in patients with rare vascular anomalies linked to PIK3CA mutations.Tiziana Life Sciences' (TLSA) intranasal foralumab showed good long-term tolerability and fatigue improvement in an expanded access program involving 14 patients with non-active secondary progressive multiple sclerosis based on updated clinical data, the company said. Its shares rose 3.7%.MetaVia (MTVA) shares were up 58% in Tuesday trading, a day after the company said three late-breaking abstracts highlighting its cardiometabolic assets were accepted for poster presentations at the American Diabetes Association's 2026 Scientific Sessions.
Healthcare stocks were leaning lower premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) slightly declining and the iShares Biotechnology ETF (IBB) down 0.3%.Relay Therapeutics (RLAY) shares were up more than 11% after the company said early phase 2 data showed its experimental drug zovegalisib reduced lesion volume in patients with rare vascular anomalies linked to PIK3CA mutations.Cullinan Therapeutics (CGEM) received the US Food and Drug Administration's orphan drug designation for its CLN-049 investigational therapy for the treatment of relapsed/refractory acute myeloid leukemia, the company said. Cullinan Therapeutics stock was up more than 2% pre-bell.Tiziana Life Sciences' (TLSA) intranasal foralumab showed good long-term tolerability and fatigue improvement in an expanded access program involving 14 patients with non-active secondary progressive multiple sclerosis based on updated clinical data, the biotechnology company said. Shares of Tiziana Life Sciences were up more than 2% premarket.
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.4% and the actively traded Invesco QQQ Trust (QQQ) was 0.7% lower in Tuesday's premarket activity amid uncertainty surrounding US-Iran negotiations.US stock futures were also lower, with S&P 500 Index futures down 0.4%, Dow Jones Industrial Average futures slipping 0.2%, and Nasdaq futures retreating 0.6% before the start of regular trading.The pending home sales data for April will be released at 10 am ET.In premarket activity, bitcoin was down by 0.2%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.3% lower, Ether ETF (EETH) retreated 0.7%, and Bitcoin & Ether Market Cap Weight ETF (BETH) declined by 0.02%.Power Play:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) retreated 1%, and the iShares US Technology ETF (IYW) was 0.6% lower, while the iShares Expanded Tech Sector ETF (IGM) was down 0.3%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) declined by 3.4%, while the iShares Semiconductor ETF (SOXX) fell by 1.7%.Agilysys (AGYS) shares were up more than 23% in premarket activity after the company overnight reported fiscal Q4 earnings and sales above market expectations.Winners and Losers:HealthcareThe State Street Health Care Select Sector SPDR ETF (XLV) retreated by 0.04%, the Vanguard Health Care Index Fund (VHT) was down 0.04%, while the iShares US Healthcare ETF (IYH) was inactive. The iShares Biotechnology ETF (IBB) was up 0.3%.Relay Therapeutics (RLAY) stock was up more than 9% premarket after the company said that the early phase 2 data showed its experimental drug zovegalisib reduced lesion volume in patients with rare vascular anomalies linked to PIK3CA mutations.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) retreated 0.1%. Direxion Daily Financial Bull 3X Shares (FAS) was down 0.01%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.1% higher.XP (XP) shares were down 5.2% in premarket activity after the company overnight reported Q1 results that fell short of analyst expectations.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.1%, and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was 0.4% lower. The iShares US Consumer Staples ETF (IYK) was flat. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.7%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was 0.7% higher.Amer Sports (AS) shares were up more than 3% pre-bell after the company reported Q1 adjusted earnings and revenue.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) retreated 0.1%, while the Vanguard Industrials Index Fund (VIS) was 0.1% lower, and the iShares US Industrials ETF (IYJ) gained 0.2%.Allegiant Travel (ALGT) stock was down more than 1% before the opening bell after the company said it is launching eight new nonstop routes beginning in fall 2026, expanding service across Florida leisure markets.EnergyThe iShares US Energy ETF (IYE) was 1.3%, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 0.4%.Equinor (EQNR) stock was up more than 1% before the opening bell after the company said it signed a 5-year agreement with Eneco to supply natural gas from the Norwegian continental shelf.CommoditiesFront-month US West Texas Intermediate crude oil retreated by 0.3% to $108.38 per barrel on the New York Mercantile Exchange. Natural gas was up 1.2% at $3.06 per 1 million British Thermal Units. The United States Oil Fund (USO) increased by 1.5%, while the United States Natural Gas Fund (UNG) was 1.2% higher.Gold futures for May retreated by 0.5% to $4,534.30 an ounce on the Comex. Silver futures fell by 1.7% to $76.13 an ounce. SPDR Gold Shares (GLD) was down by 0.3%, and the iShares Silver Trust (SLV) declined by 1.5%.
Healthcare stocks were mixed premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.1% and the iShares Biotechnology ETF (IBB) 0.3% lower.Relay Therapeutics (RLAY) shares were up more than 11% after the company said early phase 2 data showed its experimental drug zovegalisib reduced lesion volume in patients with rare vascular anomalies linked to PIK3CA mutations.
